BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37915017)

  • 21. Cefoxitin-based antibiotic therapy for extended-spectrum β-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study.
    Demonchy E; Courjon J; Ughetto E; Durand M; Risso K; Garraffo R; Roger PM
    Int J Antimicrob Agents; 2018 Jun; 51(6):836-841. PubMed ID: 29378342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia.
    Heng ST; Chen SL; Wong JGX; Lye DC; Ng TM
    Sci Rep; 2018 Aug; 8(1):12785. PubMed ID: 30143706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does Quick Sepsis-Related Organ Failure Assessment Suggest the Use of Initial Empirical Carbapenem Therapy in Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Bacteria? :A Multicenter Case-Control Study.
    Mitsuboshi S; Tsuruma N; Watanabe K; Takahashi S; Nakashita M; Ito A; Kobayashi K; Tsugita M
    Jpn J Infect Dis; 2019 Mar; 72(2):124-126. PubMed ID: 30381688
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Stewart AG; Cottrell K; Henderson A; Vemuri K; Bauer MJ; Paterson DL; Harris PNA
    Microbiol Spectr; 2021 Sep; 9(1):e0022621. PubMed ID: 34232101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
    PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome.
    Kim YK; Pai H; Lee HJ; Park SE; Choi EH; Kim J; Kim JH; Kim EC
    Antimicrob Agents Chemother; 2002 May; 46(5):1481-91. PubMed ID: 11959586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
    Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
    Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.
    Palacios-Baena ZR; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina Gil-Bermejo J; Hernández A; Venditti M; Prim N; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Paño-Pardo JR; Torre-Cisneros J; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual Á; Rodríguez-Baño J;
    Clin Infect Dis; 2017 Oct; 65(10):1615-1623. PubMed ID: 29020250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS; Lee MH; Leu HS
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High burden of ESBL and carbapenemase-producing gram-negative bacteria in bloodstream infection patients at a tertiary care hospital in Addis Ababa, Ethiopia.
    Beshah D; Desta AF; Woldemichael GB; Belachew EB; Derese SG; Zelelie TZ; Desalegn Z; Tessema TS; Gebreselasie S; Abebe T
    PLoS One; 2023; 18(6):e0287453. PubMed ID: 37368908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
    BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of extended-spectrum beta-lactamase-producing
    Siriphap A; Kitti T; Khuekankaew A; Boonlao C; Thephinlap C; Thepmalee C; Suwannasom N; Khoothiam K
    Front Cell Infect Microbiol; 2022; 12():955774. PubMed ID: 36004324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of Antibiotics for the Treatment of Bacteremia Due to Extended-spectrum β-Lactamase-producing Escherichia coli].
    Sugawara T; Murakami N; Uetake N; Hiraki K
    Yakugaku Zasshi; 2015; 135(6):829-33. PubMed ID: 26028418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity.
    To KK; Lo WU; Chan JF; Tse H; Cheng VC; Ho PL
    Int J Infect Dis; 2013 Feb; 17(2):e120-4. PubMed ID: 23098812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis.
    Zhang H; Xu J; Xiao Q; Wang Y; Wang J; Zhu M; Cai Y
    Int J Infect Dis; 2023 Mar; 128():194-204. PubMed ID: 36621752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infection.
    Marra AR; Pereira CA; Castelo A; do Carmo Filho JR; Cal RG; Sader HS; Wey SB
    Int J Infect Dis; 2006 Jan; 10(1):56-60. PubMed ID: 16326126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mortality in KPC-producing Klebsiella pneumoniae bloodstream infections: a changing landscape.
    Giacobbe DR; Marelli C; Cattardico G; Fanelli C; Signori A; Di Meco G; Di Pilato V; Mikulska M; Mazzitelli M; Cattelan AM; Pallotto C; Francisci D; Calabresi A; Lombardi A; Gori A; Del Bono V; Aldieri C; Losito AR; Raffaelli F; Cortegiani A; Milazzo M; Del Puente F; Pontali E; De Rosa FG; Corcione S; Mularoni A; Russelli G; Giacomini M; Badalucco Ciotta F; Oltolini C; Serino FS; Momesso E; Spinicci M; Graziani L; Torti C; Trecarichi EM; Merli M; D'Amico F; Marchese A; Vena A; Bassetti M
    J Antimicrob Chemother; 2023 Oct; 78(10):2505-2514. PubMed ID: 37606528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
    Johnson JK; Robinson GL; Pineles LL; Ajao AO; Zhao L; Albrecht JS; Harris AD; Thom KA; Furuno JP
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.